Solid Biosciences is trading 5.9% down at $9.75 today, pressured by a broader biotech sector decline and general risk-off sentiment among investors.
- The move extends a downward trend from last week when shares were trading above $11, despite a lack of new company-specific news or clinical updates.
- Market participants appear to be taking profits and reducing exposure to higher-risk names following the company's prior 2026 outlook and Q1 report.